List view / Grid view
In this in-depth focus are articles on consistent analytical techniques when changing laboratories and using chromatographic techniques to identify impurities in radiopharmaceuticals.
The articles in this in-depth focus explain how microbial contamination in pharmaceutical facilities can occur and discuss the impacts of temperature fluctuations on protein aggregation.
In this in-depth focus are articles exploring the global situation for drug packaging serialisation as well as an assessment of using drones to deliver medicines and how this impacts safety and quality.
Loss of manufacturing capability as a result of regulatory non-compliance can have a devastating impact on biopharma or medical device manufacturers. In this article, Jenny Yu shares real-life examples from the industry and highlights the downstream effects of these business interruptions.
According to research from the Indian Pharmaceutical Alliance, the country’s pharma sector has capacity to grow. This article investigates some of the goals, challenges and proposals the report sets out for the industry.
Within this issue is an analysis of the impacts that low temperature can have on protein aggregation, a discussion on maintaining the safety and quality of medicines when delivered using drones and an exploration of chromatographic techniques used to identify impurities in radiopharmaceuticals. Other articles focus on regulatory non-compliance, excipients…
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
Why has the pharma industry and its talents lost interest in developing new antibiotics?
Despite plans to lower drug prices in the US, political divisions have muddied the waters. This article examines the efforts made by those involved and the possibilities of their success.
This article explores the potential of readily available technology to address current traceability challenges as well as more wide-ranging issues in the pharmaceutical industry.
The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.
Janssen’s Brian Woodfall discusses the pharmaceutical company’s research process for their monthly injectable HIV treatment and their predictions for the future of the condition.
The possibilities presented by real-world data to improve drug development processes could enhance regulatory and pricing decisions for new therapeutics.
In this interview, Beth DiPaolo, President and Global Head of Eurofins Professional Scientific Services (PSS) Insourcing Solutions, provides intelligence on their global service offerings.
The Joint Pharmaceutical Analysis Group (JPAG) held a stability meeting at the Royal Society of Chemistry’s headquarters in London earlier this year. Attended by 65 delegates, its focus was on developments in stability testing and evaluation. Here follows a summary of the presentations made at the meeting.
